The Authorised Prescriber Scheme

A pathway that most people misread

The number I keep coming back to: as of late 2024, the TGA had granted more than 3,500 active Authorised Prescriber approvals in Australia. That figure covers all unapproved medicines , not just cannabis , but medicinal cannabis sits at the centre of most conversations about the scheme. And yet, when I read what's actually published about how the Authorised Prescriber (AP) Scheme works, I see a lot of shorthand that papers over real regulatory nuance.

So let me try to do it properly.

What the Authorised Prescriber Scheme actually is

Australia's therapeutic goods framework runs on a core principle: products must be entered on the Australian Register of Therapeutic Goods (ARTG) before they can lawfully be supplied. Most medicinal cannabis products are not on the ARTG , they're unapproved goods. Two main pathways exist for prescribing unapproved medicines: the Special Access Scheme (SAS) and the Authorised Prescriber Scheme.

Where the SAS typically requires a separate approval for each individual patient (SAS Category B, the most common sub-type), the AP Scheme works differently. It grants a specific medical practitioner ongoing approval to prescribe a specific unapproved medicine; or a class of such medicines, to a class of patients, without lodging a patient-by-patient application each time. The approval sits with the prescriber, not the patient or the product.

This distinction matters enormously in practice. A busy clinic prescribing to many patients is not navigating fresh TGA paperwork for each one. That is the operational point of the scheme.

The legal scaffolding

The AP Scheme operates under section 19 of the Therapeutic Goods Act 1989 (Cth). The TGA administers approvals. A practitioner must apply directly to the TGA and, in most cases, must have their application supported by a human research ethics committee (HREC) or, for medicinal cannabis specifically; by an approved college or specialist society endorsement. The TGA amended access arrangements for medicinal cannabis under the Poisons Standard several times between 2016 and 2021, progressively shifting cannabis products from Schedule 8 (Controlled Drug) for THC-dominant products and Schedule 4 (Prescription Only) for low-THC, cannabidiol-dominant products, subject to specific concentration thresholds.

Yes, there is a meaningful scheduling difference between a product where tetrahydrocannabinol (THC) is the primary cannabinoid and one where CBD dominates. That distinction shapes which regulatory obligations apply to the prescriber and how the product must be stored and recorded once dispensed.

What an AP approval covers, and what it does not

An AP approval names the prescriber, specifies the unapproved medicine or medicine class, and defines the class of patients who may receive it. It does not compel any patient to seek out that prescriber. It does not guarantee that any particular product is appropriate for any particular person, clinical judgement remains entirely with the doctor.

The approval also does not override state and territory law. Each jurisdiction overlays its own controlled-drugs legislation on top of the federal framework. An AP approval granted under the Therapeutic Goods Act by the TGA does not, by itself, satisfy the separate permit or authority requirements that some states impose under their own Poisons and Therapeutic Goods Acts. Practitioners need to check both layers. Honestly, this is one of the areas where I think the public-facing explanations of the scheme fall short; the dual-layer obligation is real and it catches people out.

How AP differs from SAS Category B in practice

I find it useful to think of SAS Cat B as the default one-off mechanism and the AP Scheme as a standing arrangement earned through demonstrated clinical context. For a practitioner new to prescribing medicinal cannabis, SAS Cat B is often the first port of call; it requires the prescriber to notify the TGA (since the August 2020 reclassification lowered the bar for unapproved cannabis) and keep records, but doesn't need HREC sign-off. The AP pathway asks more upfront, that supporting endorsement, the specific class-of-patient framing, but removes the per-patient friction thereafter.

The TGA publishes AP approval data in aggregate. That data shows the specialty spread of approving practitioners; GPs hold the largest share, but the scheme reaches into pain medicine, psychiatry, neurology, and palliative care. Each AP holder is also required to submit six-monthly reports to the TGA on the number of patients they've treated under the approval. That reporting obligation is where a lot of the real-world prescribing data actually originates.

Product requirements: GMP and the ARTG question

Even under the AP Scheme, the product being supplied must meet certain manufacturing standards. Products supplied via unapproved pathways are still expected to be manufactured under Good Manufacturing Practice (GMP) conditions, the TGA enforces this. An AP approval for an unapproved medicine is not a licence to supply anything of unknown provenance; it's a clinical access pathway for goods that haven't completed the full ARTG registration process, which is a very different thing.

For cannabis specifically, products with more than 2% THC are Schedule 8. Those below the threshold, predominantly CBD isolates or broad-spectrum preparations; may be Schedule 4, depending on exact formulation. The pharmacokinetic profile of any given formulation, including factors like bioavailability and first-pass metabolism, is separate from its scheduling classification, though it's relevant to clinical decision-making that sits entirely with the prescriber.

The 2020–2021 changes and where we are now

I was working on a policy brief for a Canberra health directorate in mid-2020 when the TGA changed the notification pathway for unapproved cannabis under SAS Cat B, it was, in policy terms, a significant loosening of administrative load. The AP Scheme itself received attention through the same period as prescriber numbers grew. By 2021, the TGA had also issued clearer guidance on the AP application process for cannabis, including how practitioners could reference specialist college endorsements.

Between Trevor (my sourdough starter, running strong since 2019) and the stack of Poisons Standard amendments on my desk, those years were genuinely busy. But the regulatory architecture that emerged is cleaner than what preceded it, and understanding it accurately matters for anyone working in or around this space.

One thing worth flagging: the AP Scheme is not static. The TGA reviews and can revoke approvals. Practitioners are expected to maintain currency with evidence, adhere to their six-monthly reporting, and remain within the patient class specified in their approval. It is not a set-and-forget arrangement.

What the scheme does not do

A standing AP approval doesn't say anything about whether any particular medicine is right for any particular patient. That assessment is a matter for the prescribing practitioner alone, drawing on the patient's full clinical picture. This article is a regulatory explanation; not a clinical recommendation, not a prompt to seek any prescription, and not a commentary on whether any individual should or shouldn't pursue a medicinal cannabis consultation. The TGA's role is regulatory; clinical judgement is the practitioner's.

If you want to understand how the endocannabinoid system functions at a mechanistic level, which is genuinely relevant context for understanding why certain cannabinoid classes attract different scheduling treatment, that's worth reading separately. The scheduling framework and the pharmacology are two distinct layers, and conflating them is a frequent source of confusion in public commentary about this area.

Sources

• About the Authorised Prescriber Scheme; Therapeutic Goods Administration (TGA)
• Access to Medicinal Cannabis Products: Questions and Answers, TGA
• Regulation of Medicinal Cannabis in Australia, Australian Government Department of Health
• Therapeutic Goods (Poisons Standard; Cannabis and Other Matters) Amendment 2021, Federal Register of Legislation

, Marcus Hale, Regulatory researcher, TGA & access law